ArticleLeukemia & lymphoma2015
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.
Article in Leukemia & lymphoma, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.Acta haematologica · 2025Article
- Cytogenetic findings in testicular relapse of multiple myeloma: case report and literature review.Hematology, transfusion and cell therapy · 2024Article
- GFI1-Dependent Repression ofCancers · 2022Article
- A simple additive staging system for newly diagnosed multiple myeloma.Blood cancer journal · 2022Article
- The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.Haematologica · 2021Article
- Review
- Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.Journal of molecular medicine (Berlin, Germany) · 2020Article
- c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.European journal of haematology · 2020Article
- Molecular basis of clonal evolution in multiple myeloma.International journal of hematology · 2020Review
- Double-Hit Primary Plasma Cell Leukemia withCase reports in hematology · 2020Article
- Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma.Blood cancer journal · 2019Article
- Article
- Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data.Genome research · 2018Article
- Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.Mediterranean journal of hematology and infectious diseases · 2018Review
- Article
- Evolutionary biology of high-risk multiple myeloma.Nature reviews. Cancer · 2017Review
- RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.British journal of haematology · 2017Article
- Prognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
The proto-oncogene c-MYC is rearranged in about 15% of patients with multiple myeloma (MM). We identified 23 patients with MM and c-MYC. Primary objectives were to describe the clinical characteristics, response to therapy, progression-free survival and overall survival (OS). Twelve out of twenty-three patients presented with or progressed to either plasma cell leukemia (PCL) and/or extramedullary disease (EMD). Induction therapy consisted of an immunomodulatory, proteasome inhibitor-based or conventional chemotherapy regimen. Fifteen patients achieved a partial response and three achieved a very good partial response. Sixteen patients received an autologous and one patient an allogeneic hematopoietic stem cell transplant. Median OS from diagnosis was 20.2 months. Patients with PCL or EMD had significantly shorter OS (15.5 vs. 40.4 months, p = 0.0005). This is the first report describing the clinical characteristics of patients with MM and c-MYC. These abnormalities are associated with an aggressive form of MM, high incidence of PCL/EMD and short OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.